Enoxaparin in ACS
Enoxaparin in ACS
Enoxaparin in ACS
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Is UFH the choice when us<strong>in</strong>g SK?o SK + S.C. Hepar<strong>in</strong> didn’t improve outcomecompared with hepar<strong>in</strong>oGISSI- 2oISIS- 3o SK + I.V. Hepar<strong>in</strong> didn’t improve outcomeoGUSTO- 1o SK + I.V. Hepar<strong>in</strong> <strong>in</strong>crease the tendency formajor bleed<strong>in</strong>gAMI-SK Study designSTEMI(n=496)SK1.5 MU i.v.1 h+ aspir<strong>in</strong>(30 days)(n=491)<strong>Enoxapar<strong>in</strong></strong>30 mgbolus Angiography Follow-upi.v., thenday 8day 301 mg/kg s.c.q 12 h(3–8 days)(n=252)Placebo(3–8 days)(n=239)Angiographyday 8Follow-upday 30SK: Streptok<strong>in</strong>aseTreatment phaseFollow-up phase
Change language